Brokers Offer Predictions for Marinus Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Leerink Partnrs lifted their Q1 2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research report issued to clients and investors on Monday, April 15th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of ($0.61) per share for the quarter, up from their prior estimate of ($0.64). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.37) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.70) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.65 EPS.

MRNS has been the topic of a number of other reports. StockNews.com cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th. Royal Bank of Canada reiterated a “sector perform” rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday. Robert W. Baird reaffirmed a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $18.21.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $1.44 on Thursday. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07. The stock’s fifty day simple moving average is $8.72 and its 200 day simple moving average is $8.45. Marinus Pharmaceuticals has a 52-week low of $1.11 and a 52-week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The firm had revenue of $7.19 million during the quarter, compared to the consensus estimate of $7.78 million. During the same period in the prior year, the firm posted ($0.76) EPS.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Large investors have recently made changes to their positions in the business. FMR LLC lifted its position in shares of Marinus Pharmaceuticals by 1,887.9% during the 1st quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 4,210 shares during the last quarter. BluePath Capital Management LLC acquired a new position in shares of Marinus Pharmaceuticals during the 3rd quarter worth about $38,000. Quantbot Technologies LP acquired a new position in shares of Marinus Pharmaceuticals during the 1st quarter worth about $40,000. Ameritas Investment Partners Inc. acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $45,000. Finally, Jane Street Group LLC acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth about $47,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.